H2BC11
gene geneOn this page
Also known as H2B/r
Summary
H2BC11 (H2B clustered histone 11, HGNC:4761) is a protein-coding gene on chromosome 6p22.1, encoding Histone H2B type 1-J (P06899). Core component of nucleosome. It is a common-essential gene (DepMap: required in 99.4% of cancer cell lines).
Histones are basic nuclear proteins that are responsible for the nucleosome structure of the chromosomal fiber in eukaryotes. Two molecules of each of the four core histones (H2A, H2B, H3, and H4) form an octamer, around which approximately 146 bp of DNA is wrapped in repeating units, called nucleosomes. The linker histone, H1, interacts with linker DNA between nucleosomes and functions in the compaction of chromatin into higher order structures. This gene is intronless and encodes a replication-dependent histone that is a member of the histone H2B family. Transcripts from this gene lack polyA tails but instead contain a palindromic termination element. This gene is found in the histone microcluster on chromosome 6p21.33.
Source: NCBI Gene 8970 — RefSeq curated summary.
At a glance
- GWAS associations: 24
- Clinical variants (ClinVar): 25 total
- Cancer dependency (DepMap): dependent in 99.4% of screened cell lines (common-essential)
- MANE Select transcript:
NM_021058
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:4761 |
| Approved symbol | H2BC11 |
| Name | H2B clustered histone 11 |
| Location | 6p22.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | H2B/r |
| Ensembl gene | ENSG00000124635 |
| Ensembl biotype | protein_coding |
| OMIM | 615044 |
| Entrez | 8970 |
Gene structure
Transcript identifiers
Ensembl transcripts: 4 — 4 protein_coding
ENST00000339812, ENST00000606923, ENST00000607124, ENST00000939860
RefSeq mRNA: 1 — MANE Select: NM_021058
NM_021058
CCDS: CCDS4618
Canonical transcript exons
ENST00000339812 — 1 exons
| Exon | Start | End |
|---|---|---|
| ENSE00002255833 | 27132316 | 27132795 |
Expression profiles
Bgee: expression breadth ubiquitous, 138 present calls, max score 98.73.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 246.8781 / max 6879.1525, expressed in 1813 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 72355 | 246.8781 | 1813 |
Top tissues by expression
153 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| bone marrow cell | CL:0002092 | 98.73 | gold quality |
| monocyte | CL:0000576 | 95.66 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 95.39 | gold quality |
| calcaneal tendon | UBERON:0003701 | 95.28 | gold quality |
| leukocyte | CL:0000738 | 94.51 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 93.45 | gold quality |
| left testis | UBERON:0004533 | 93.15 | gold quality |
| right testis | UBERON:0004534 | 93.09 | gold quality |
| testis | UBERON:0000473 | 92.57 | gold quality |
| adrenal tissue | UBERON:0018303 | 92.38 | gold quality |
| blood | UBERON:0000178 | 89.87 | gold quality |
| bone marrow | UBERON:0002371 | 87.18 | gold quality |
| granulocyte | CL:0000094 | 83.13 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 81.99 | gold quality |
| corpus callosum | UBERON:0002336 | 80.58 | gold quality |
| tonsil | UBERON:0002372 | 80.39 | gold quality |
| colonic epithelium | UBERON:0000397 | 79.88 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 78.25 | gold quality |
| vagina | UBERON:0000996 | 78.11 | gold quality |
| spleen | UBERON:0002106 | 77.99 | gold quality |
| right lung | UBERON:0002167 | 77.73 | gold quality |
| esophagus mucosa | UBERON:0002469 | 76.23 | gold quality |
| gastrocnemius | UBERON:0001388 | 76.12 | gold quality |
| muscle of leg | UBERON:0001383 | 75.98 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 75.97 | gold quality |
| spinal cord | UBERON:0002240 | 75.74 | gold quality |
| prostate gland | UBERON:0002367 | 74.39 | gold quality |
| lung | UBERON:0002048 | 74.37 | gold quality |
| uterine cervix | UBERON:0000002 | 74.29 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 73.24 | gold quality |
Single-cell (SCXA)
Detected in 4 experiment(s), a significant marker in 3.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-CURD-122 | yes | 21.36 |
| E-ANND-3 | yes | 7.76 |
| E-HCAD-1 | yes | 5.56 |
| E-GEOD-124858 | no | 12.77 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): E2F1, E2F4, EZH2, HEY1, POU2F1, POU2F2, PPARA, TP53
Functional genomics
DepMap (CRISPR cell-line fitness): dependent in 99.4% of screened cell lines, common-essential.
Literature-anchored findings (GeneRIF, showing 2)
- Histone H2A and H2B antimicrobial peptides exhibit antibacterial activity and endotoxin-neutralizing activity in the placenta. (PMID:11859126)
- The genes HIST1H2BJ, PRSS16, and PGBD1 were not associated with Japanese patients with schizophrenia. (PMID:22488895)
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | H2bc21 | ENSMUSG00000068854 |
| rattus_norvegicus | ENSRNOG00000075829 |
Paralogs (21): H2BW2 (ENSG00000101812), H2BW1 (ENSG00000123569), H2BC1 (ENSG00000146047), H2BC5 (ENSG00000158373), H2BC4 (ENSG00000180596), H2BC21 (ENSG00000184678), H2BC13 (ENSG00000185130), H2BC26 (ENSG00000196890), H2BC12 (ENSG00000197903), H2BC18 (ENSG00000203814), H2BC15 (ENSG00000233822), H2BC12L (ENSG00000234289), H2BC14 (ENSG00000273703), H2BC8 (ENSG00000273802), H2BC6 (ENSG00000274290), H2BC17 (ENSG00000274641), H2BC9 (ENSG00000275713), H2BC3 (ENSG00000276410), H2BC7 (ENSG00000277224), H2BC10 (ENSG00000278588), H2BK1 (ENSG00000285480)
Protein
Protein identifiers
Histone H2B type 1-J — P06899 (reviewed: P06899)
Alternative names: Histone H2B.1, Histone H2B.r
All UniProt accessions (2): P06899, U3KPT8
UniProt curated annotations — full annotation on UniProt →
Function. Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. Has broad antibacterial activity. May contribute to the formation of the functional antimicrobial barrier of the colonic epithelium, and to the bactericidal activity of amniotic fluid.
Subunit / interactions. The nucleosome is a histone octamer containing two molecules each of H2A, H2B, H3 and H4 assembled in one H3-H4 heterotetramer and two H2A-H2B heterodimers. The octamer wraps approximately 147 bp of DNA. Heterodimer H2BC11 and H2AZ1 interacts with VPS72 (via N-terminal domain).
Subcellular location. Nucleus. Chromosome.
Post-translational modifications. Monoubiquitination at Lys-35 (H2BK34Ub) by the MSL1/MSL2 dimer is required for histone H3 ‘Lys-4’ (H3K4me) and ‘Lys-79’ (H3K79me) methylation and transcription activation at specific gene loci, such as HOXA9 and MEIS1 loci. Similarly, monoubiquitination at Lys-121 (H2BK120Ub) by the RNF20/40 complex gives a specific tag for epigenetic transcriptional activation and is also prerequisite for histone H3 ‘Lys-4’ and ‘Lys-79’ methylation. It also functions cooperatively with the FACT dimer to stimulate elongation by RNA polymerase II. H2BK120Ub also acts as a regulator of mRNA splicing: deubiquitination by USP49 is required for efficient cotranscriptional splicing of a large set of exons. Phosphorylation at Ser-37 (H2BS36ph) by AMPK in response to stress promotes transcription. Phosphorylated on Ser-15 (H2BS14ph) by STK4/MST1 during apoptosis; which facilitates apoptotic chromatin condensation. Also phosphorylated on Ser-15 in response to DNA double strand breaks (DSBs), and in correlation with somatic hypermutation and immunoglobulin class-switch recombination. GlcNAcylation at Ser-113 promotes monoubiquitination of Lys-121. It fluctuates in response to extracellular glucose, and associates with transcribed genes. ADP-ribosylated by PARP1 or PARP2 on Ser-7 (H2BS6ADPr) in response to DNA damage. H2BS6ADPr promotes recruitment of CHD1L. Mono-ADP-ribosylated on Glu-3 (H2BE2ADPr) by PARP3 in response to single-strand breaks. Poly ADP-ribosylation on Glu-36 (H2BE35ADPr) by PARP1 regulates adipogenesis: it inhibits phosphorylation at Ser-37 (H2BS36ph), thereby blocking expression of pro-adipogenetic genes. Crotonylation (Kcr) is specifically present in male germ cells and marks testis-specific genes in post-meiotic cells, including X-linked genes that escape sex chromosome inactivation in haploid cells. Crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors. It is also associated with post-meiotically activated genes on autosomes. Lactylated in macrophages by EP300/P300 by using lactoyl-CoA directly derived from endogenous or exogenous lactate, leading to stimulates gene transcription.
Similarity. Belongs to the histone H2B family.
RefSeq proteins (1): NP_066402* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000558 | Histone_H2B | Family |
| IPR007125 | H2A/H2B/H3 | Domain |
| IPR009072 | Histone-fold | Homologous_superfamily |
| IPR055333 | HISTONE_H2B_site | Conserved_site |
Pfam: PF00125
UniProt features (109 total): modified residue 91, helix 4, cross-link 4, strand 3, initiator methionine 1, chain 1, sequence conflict 1, turn 1, region of interest 1, compositionally biased region 1, glycosylation site 1
Structure
Experimental structures (PDB)
304 structures, top 30 by resolution.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 4CAY | X-RAY DIFFRACTION | 1.48 |
| 7VZ4 | ELECTRON MICROSCOPY | 1.89 |
| 8I17 | X-RAY DIFFRACTION | 1.98 |
| 5B0Z | X-RAY DIFFRACTION | 1.99 |
| 5Y0D | X-RAY DIFFRACTION | 1.99 |
| 6IPU | X-RAY DIFFRACTION | 1.99 |
| 9INC | X-RAY DIFFRACTION | 2.01 |
| 5Y0C | X-RAY DIFFRACTION | 2.09 |
| 6JOU | X-RAY DIFFRACTION | 2.17 |
| 5X7X | X-RAY DIFFRACTION | 2.18 |
| 5AV6 | X-RAY DIFFRACTION | 2.2 |
| 5AV8 | X-RAY DIFFRACTION | 2.2 |
| 5AV9 | X-RAY DIFFRACTION | 2.2 |
| 5B31 | X-RAY DIFFRACTION | 2.2 |
| 6K1K | X-RAY DIFFRACTION | 2.2 |
| 6KVD | X-RAY DIFFRACTION | 2.21 |
| 6IQ4 | X-RAY DIFFRACTION | 2.25 |
| 6JXD | X-RAY DIFFRACTION | 2.25 |
| 8KB5 | ELECTRON MICROSCOPY | 2.26 |
| 5B32 | X-RAY DIFFRACTION | 2.35 |
| 8JLB | ELECTRON MICROSCOPY | 2.36 |
| 8YBJ | ELECTRON MICROSCOPY | 2.38 |
| 3AZG | X-RAY DIFFRACTION | 2.4 |
| 5AV5 | X-RAY DIFFRACTION | 2.4 |
| 5AVB | X-RAY DIFFRACTION | 2.4 |
| 5AVC | X-RAY DIFFRACTION | 2.4 |
| 6JR1 | X-RAY DIFFRACTION | 2.4 |
| 5Z30 | X-RAY DIFFRACTION | 2.45 |
| 8JLD | ELECTRON MICROSCOPY | 2.48 |
| 8VG1 | ELECTRON MICROSCOPY | 2.48 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P06899-F1 | 85.70 | 0.71 |
Antibody-complex structures (SAbDab): 8 — 6E0C, 6E0P, 7K5X, 7K5Y, 7K60, 7K61, 7K63, 8VFX
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (95): 6, 6, 6, 6, 7, 12, 12, 12, 12, 12, 12, 13, 13, 13, 15, 16, 16, 16, 16, 17 …
Glycosylation sites (1): 113
Function
Pathways and Gene Ontology
Reactome pathways
58 pathways
| ID | Pathway |
|---|---|
| R-HSA-110328 | Recognition and association of DNA glycosylase with site containing an affected pyrimidine |
| R-HSA-110329 | Cleavage of the damaged pyrimidine |
| R-HSA-110330 | Recognition and association of DNA glycosylase with site containing an affected purine |
| R-HSA-110331 | Cleavage of the damaged purine |
| R-HSA-1221632 | Meiotic synapsis |
| R-HSA-171306 | Packaging Of Telomere Ends |
| R-HSA-1912408 | Pre-NOTCH Transcription and Translation |
| R-HSA-201722 | Formation of the beta-catenin:TCF transactivating complex |
| R-HSA-212300 | PRC2 methylates histones and DNA |
| R-HSA-2299718 | Condensation of Prophase Chromosomes |
| R-HSA-2559580 | Oxidative Stress Induced Senescence |
| R-HSA-2559582 | Senescence-Associated Secretory Phenotype (SASP) |
| R-HSA-2559586 | DNA Damage/Telomere Stress Induced Senescence |
| R-HSA-3214815 | HDACs deacetylate histones |
| R-HSA-3214847 | HATs acetylate histones |
| R-HSA-427359 | SIRT1 negatively regulates rRNA expression |
| R-HSA-427389 | ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression |
| R-HSA-427413 | NoRC negatively regulates rRNA expression |
| R-HSA-5250924 | B-WICH complex positively regulates rRNA expression |
| R-HSA-5334118 | DNA methylation |
| R-HSA-5578749 | Transcriptional regulation by small RNAs |
| R-HSA-5617472 | Activation of anterior HOX genes in hindbrain development during early embryogenesis |
| R-HSA-5625886 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 |
| R-HSA-5689880 | Ub-specific processing proteases |
| R-HSA-5693565 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks |
| R-HSA-5693571 | Nonhomologous End-Joining (NHEJ) |
| R-HSA-5693607 | Processing of DNA double-strand break ends |
| R-HSA-606279 | Deposition of new CENPA-containing nucleosomes at the centromere |
| R-HSA-68616 | Assembly of the ORC complex at the origin of replication |
| R-HSA-69473 | G2/M DNA damage checkpoint |
MSigDB gene sets: 284 (showing top):
BROWNE_HCMV_INFECTION_30MIN_DN, REACTOME_MEIOTIC_RECOMBINATION, REACTOME_DNA_REPLICATION, REACTOME_SIGNALING_BY_NOTCH, GOBP_ANTIMICROBIAL_HUMORAL_RESPONSE, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_MEIOTIC_SYNAPSIS, GOBP_RESPONSE_TO_PEPTIDE, ENK_UV_RESPONSE_KERATINOCYTE_UP, REACTOME_G2_M_DNA_DAMAGE_CHECKPOINT, GOBP_NEGATIVE_REGULATION_OF_TUMOR_NECROSIS_FACTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_ORGAN_OR_TISSUE_SPECIFIC_IMMUNE_RESPONSE, REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP
GO Biological Process (11): innate immune response in mucosa (GO:0002227), chromatin organization (GO:0006325), nucleosome assembly (GO:0006334), negative regulation of tumor necrosis factor-mediated signaling pathway (GO:0010804), antibacterial humoral response (GO:0019731), killing of cells of another organism (GO:0031640), defense response to Gram-negative bacterium (GO:0050829), defense response to Gram-positive bacterium (GO:0050830), protein localization to CENP-A containing chromatin (GO:0061644), antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844), defense response to bacterium (GO:0042742)
GO Molecular Function (5): lipopolysaccharide binding (GO:0001530), DNA binding (GO:0003677), structural constituent of chromatin (GO:0030527), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515)
GO Cellular Component (8): nucleosome (GO:0000786), obsolete extracellular space (GO:0005615), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), CENP-A containing nucleosome (GO:0043505), chromosome (GO:0005694), plasma membrane (GO:0005886)
Reactome top-level categories
Rollup of top-12 pathways:
| Category | Pathways |
|---|---|
| Cellular Senescence | 3 |
| Depyrimidination | 2 |
| Depurination | 2 |
| Epigenetic regulation of gene expression | 2 |
| Chromatin modifying enzymes | 2 |
| Negative epigenetic regulation of rRNA expression | 2 |
| Positive epigenetic regulation of rRNA expression | 2 |
| Meiosis | 1 |
| Telomere Maintenance | 1 |
| Pre-NOTCH Expression and Processing | 1 |
| TCF dependent signaling in response to WNT | 1 |
| Mitotic Prophase | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| defense response to bacterium | 3 |
| antimicrobial humoral response | 2 |
| chromatin | 2 |
| cellular anatomical structure | 2 |
| mucosal immune response | 1 |
| innate immune response | 1 |
| cellular component organization | 1 |
| chromatin organization | 1 |
| nucleosome organization | 1 |
| protein-DNA complex assembly | 1 |
| negative regulation of cytokine-mediated signaling pathway | 1 |
| regulation of tumor necrosis factor-mediated signaling pathway | 1 |
| tumor necrosis factor-mediated signaling pathway | 1 |
| cell killing | 1 |
| disruption of cell in another organism | 1 |
| protein localization to chromatin | 1 |
| protein localization to chromosome, centromeric region | 1 |
| defense response | 1 |
| response to bacterium | 1 |
| lipid binding | 1 |
| carbohydrate derivative binding | 1 |
| nucleic acid binding | 1 |
| structural molecule activity | 1 |
| protein dimerization activity | 1 |
| binding | 1 |
| protein-DNA complex | 1 |
| intracellular membrane-bounded organelle | 1 |
| nuclear lumen | 1 |
| cytoplasm | 1 |
| nucleosome | 1 |
| CENP-A containing chromatin | 1 |
| intracellular membraneless organelle | 1 |
| membrane | 1 |
| cell periphery | 1 |
Protein interactions and networks
STRING
2420 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| H2BC11 | PLG | P00747 | 874 |
| H2BC11 | RNF20 | Q5VTR2 | 836 |
| H2BC11 | H3C1 | P02295 | 816 |
| H2BC11 | H3C14 | Q71DI3 | 809 |
| H2BC11 | H3-7 | Q5TEC6 | 809 |
| H2BC11 | H3-3A | P06351 | 808 |
| H2BC11 | H3-5 | Q6NXT2 | 808 |
| H2BC11 | H3-4 | Q16695 | 808 |
| H2BC11 | RNF40 | O75150 | 772 |
| H2BC11 | H2AC19 | P20670 | 762 |
| H2BC11 | H2AC20 | Q16777 | 756 |
| H2BC11 | H4C16 | P02304 | 747 |
| H2BC11 | H4C7 | Q99525 | 744 |
| H2BC11 | DET1 | Q7L5Y6 | 725 |
| H2BC11 | USP22 | Q9UPT9 | 722 |
IntAct
109 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| H2AC4 | H2BC11 | psi-mi:“MI:0915”(physical association) | 0.850 |
| H2AC4 | H2BC11 | psi-mi:“MI:0407”(direct interaction) | 0.850 |
| H2AX | PPM1G | psi-mi:“MI:0914”(association) | 0.730 |
| H2AC4 | PPM1G | psi-mi:“MI:0914”(association) | 0.670 |
| H2BC1 | PPM1G | psi-mi:“MI:0914”(association) | 0.640 |
| CBX1 | ZNF292 | psi-mi:“MI:0914”(association) | 0.530 |
| MACROH2A2 | PPM1G | psi-mi:“MI:0914”(association) | 0.530 |
| H2AC18 | PPM1G | psi-mi:“MI:0914”(association) | 0.530 |
| VCAM1 | PSMD11 | psi-mi:“MI:0914”(association) | 0.530 |
| ERBB2 | HAX1 | psi-mi:“MI:0914”(association) | 0.530 |
| psi-mi:“MI:0915”(physical association) | 0.500 | ||
| ACTR5 | H2AC4 | psi-mi:“MI:0915”(physical association) | 0.460 |
| ACTR5 | H2AC4 | psi-mi:“MI:0914”(association) | 0.460 |
| ANP32E | H2BC11 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| PPM1G | H2BC12 | psi-mi:“MI:0914”(association) | 0.420 |
| PPM1G | H2BC12 | psi-mi:“MI:2364”(proximity) | 0.420 |
| H2BC11 | TLX3 | psi-mi:“MI:0915”(physical association) | 0.370 |
| JMJD6 | H2BC11 | psi-mi:“MI:0915”(physical association) | 0.370 |
| CREB1 | NFIX | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (400): HIST1H2BJ (Affinity Capture-MS), HIST1H2BJ (Affinity Capture-MS), HIST1H2BJ (Affinity Capture-MS), HIST1H2BJ (Affinity Capture-MS), HIST1H2BJ (Affinity Capture-MS), HIST1H2BJ (Affinity Capture-MS), HIST1H2BJ (Affinity Capture-MS), HIST1H2BJ (Biochemical Activity), PARP9 (Affinity Capture-Western), DTX3L (Affinity Capture-Western), STAT1 (Affinity Capture-Western), HIST1H2BJ (Affinity Capture-Western), FGA (Affinity Capture-MS), FGB (Affinity Capture-MS), FGG (Affinity Capture-MS)
ESM2 similar proteins: A1CJ09, A1D8G9, A2QY49, A3LXE6, A3LZZ1, A5DBG5, A5DJJ1, A5DWF0, L7I1W3, P02281, P02293, P02294, P04255, P04913, P06899, P0C1H5, P0CO02, P0CO03, P0CT13, P10853, P23754, P37210, P48989, P78567, Q0CBD1, Q1E5N0, Q1SU99, Q27484, Q27876, Q27894, Q2HH38, Q2U5A9, Q43217, Q4HTT2, Q4PEF8, Q4WWC5, Q59VP1, Q5RCP8, Q6BKW7, Q6BRG2
Diamond homologs: A0A2R8Y619, A2WKT1, A2WKT4, A2WWU2, A2XF66, A2YWI3, A3AGM4, O22582, O60814, O65819, P02281, P02283, P02284, P02285, P02286, P02287, P02288, P02289, P02290, P04255, P06145, P06899, P06900, P07794, P07795, P0C1H3, P0C1H4, P0C1H5, P10853, P10854, P14001, P16888, P16889, P16890, P17271, P19374, P21897, P23527, P27326, P27807
SIGNOR signaling
8 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| H2BC11 | “form complex” | “Nucleosome_H3.3 variant” | binding |
| SLBP | “up-regulates quantity by expression” | H2BC11 | “translation regulation” |
| “MSL acetyltransferase” | “down-regulates activity” | H2BC11 | monoubiquitination |
| H2BC11 | “form complex” | “CENP-A nucleosome” | binding |
| H2BC11 | “form complex” | “Nucleosome_H2A.Z.2 variant” | binding |
| H2BC11 | “form complex” | “Nucleosome_H2A.Z.1 variant” | binding |
| H2BC11 | “form complex” | “Nucleosome_H3.1 variant” | binding |
| H2BC11 | “form complex” | “Nucleosome_H3.1t variant” | binding |
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 100 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Transcriptional regulation of granulopoiesis | 11 | 19.2× | 6e-09 |
| ChAHP complex assembly | 6 | 15.3× | 2e-04 |
| Packaging Of Telomere Ends | 5 | 15.2× | 8e-04 |
| SIRT1 negatively regulates rRNA expression | 6 | 14.2× | 3e-04 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 5 | 14.2× | 9e-04 |
| Cleavage of the damaged purine | 5 | 14.2× | 9e-04 |
| Inhibition of DNA recombination at telomere | 6 | 14.0× | 3e-04 |
| Regulation of PD-L1(CD274) transcription | 9 | 13.6× | 6e-06 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| mRNA transcription by RNA polymerase II | 5 | 18.6× | 2e-03 |
| heterochromatin formation | 6 | 17.2× | 7e-04 |
| positive regulation of miRNA transcription | 5 | 16.3× | 2e-03 |
| response to ethanol | 7 | 11.5× | 9e-04 |
| nucleosome assembly | 6 | 9.5× | 5e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
25 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 25 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
409 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 6:27132365:A:AC | donor_gain | 1.0000 |
| 6:27132366:C:CC | donor_gain | 1.0000 |
| 6:27132376:A:AC | donor_gain | 1.0000 |
| 6:27132376:AG:A | donor_gain | 1.0000 |
| 6:27132376:AGCG:A | donor_gain | 1.0000 |
| 6:27132377:G:C | donor_gain | 1.0000 |
| 6:27126459:CCAC:C | acceptor_gain | 0.9900 |
| 6:27126460:CACC:C | acceptor_gain | 0.9900 |
| 6:27132361:ACT:A | donor_loss | 0.9900 |
| 6:27132362:C:G | donor_loss | 0.9900 |
| 6:27132362:CTCA:C | donor_gain | 0.9900 |
| 6:27132363:TCACT:T | donor_loss | 0.9900 |
| 6:27132364:CA:C | donor_loss | 0.9900 |
| 6:27132365:AC:A | donor_loss | 0.9900 |
| 6:27132366:CT:C | donor_gain | 0.9900 |
| 6:27132366:CTG:C | donor_gain | 0.9900 |
| 6:27132372:A:AC | donor_gain | 0.9900 |
| 6:27132373:C:CC | donor_gain | 0.9900 |
| 6:27132390:TGGTG:T | donor_gain | 0.9900 |
| 6:27132403:AGTAC:A | donor_gain | 0.9900 |
| 6:27126460:CAC:C | acceptor_gain | 0.9800 |
| 6:27126460:CACCT:C | acceptor_loss | 0.9800 |
| 6:27126461:ACC:A | acceptor_loss | 0.9800 |
| 6:27126463:C:CC | acceptor_gain | 0.9800 |
| 6:27126463:CT:C | acceptor_loss | 0.9800 |
| 6:27126464:T:G | acceptor_loss | 0.9800 |
| 6:27127401:CCTT:C | acceptor_gain | 0.9800 |
| 6:27127400:CCCTT:C | acceptor_gain | 0.9700 |
| 6:27127412:C:CT | acceptor_gain | 0.9700 |
| 6:27127413:A:T | acceptor_gain | 0.9700 |
AlphaMissense
814 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 6:27132400:C:A | K117N | 1.000 |
| 6:27132400:C:G | K117N | 1.000 |
| 6:27132407:C:A | G115V | 1.000 |
| 6:27132407:C:T | G115D | 1.000 |
| 6:27132408:C:A | G115C | 1.000 |
| 6:27132408:C:G | G115R | 1.000 |
| 6:27132419:G:T | A111D | 1.000 |
| 6:27132431:A:C | L107W | 1.000 |
| 6:27132431:A:G | L107S | 1.000 |
| 6:27132437:C:A | G105V | 1.000 |
| 6:27132437:C:T | G105E | 1.000 |
| 6:27132438:C:A | G105W | 1.000 |
| 6:27132449:A:G | L101P | 1.000 |
| 6:27132458:G:T | A98D | 1.000 |
| 6:27132459:C:G | A98P | 1.000 |
| 6:27132463:C:A | Q96H | 1.000 |
| 6:27132463:C:G | Q96H | 1.000 |
| 6:27132471:C:T | E94K | 1.000 |
| 6:27132472:C:A | R93S | 1.000 |
| 6:27132472:C:G | R93S | 1.000 |
| 6:27132473:C:A | R93M | 1.000 |
| 6:27132519:C:G | A78P | 1.000 |
| 6:27132545:T:A | D69V | 1.000 |
| 6:27132608:T:G | Q48P | 1.000 |
| 6:27132614:A:G | L46P | 1.000 |
| 6:27132395:A:T | V119D | 0.999 |
| 6:27132398:G:T | A118D | 0.999 |
| 6:27132399:C:G | A118P | 0.999 |
| 6:27132402:T:C | K117E | 0.999 |
| 6:27132404:G:A | T116I | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000107163 (6:27131958 G>A), RS1001283944 (6:27133597 C>T), RS1001313399 (6:27133468 T>C), RS1002289581 (6:27134532 T>C), RS1002319247 (6:27134237 A>C), RS1004388343 (6:27134226 A>G), RS1004761593 (6:27134472 T>G), RS1005075620 (6:27132276 C>T), RS1006198827 (6:27133752 A>G), RS1006537220 (6:27131999 G>A,C), RS1006766102 (6:27132233 CA>C,CAA), RS1007849734 (6:27133891 G>A,T), RS1008207013 (6:27132727 A>G), RS1008298911 (6:27132812 G>A), RS1008424451 (6:27133744 A>G)
Disease associations
OMIM: gene MIM:615044 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
24 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST000301_13 | Iron status biomarkers | 1.000000e-08 |
| GCST000433_1 | Schizophrenia | 1.000000e-08 |
| GCST004521_113 | Autism spectrum disorder or schizophrenia | 3.000000e-19 |
| GCST004521_116 | Autism spectrum disorder or schizophrenia | 3.000000e-16 |
| GCST004521_166 | Autism spectrum disorder or schizophrenia | 4.000000e-24 |
| GCST004521_208 | Autism spectrum disorder or schizophrenia | 5.000000e-17 |
| GCST004521_215 | Autism spectrum disorder or schizophrenia | 5.000000e-13 |
| GCST004521_286 | Autism spectrum disorder or schizophrenia | 5.000000e-08 |
| GCST004521_57 | Autism spectrum disorder or schizophrenia | 1.000000e-20 |
| GCST004521_69 | Autism spectrum disorder or schizophrenia | 8.000000e-24 |
| GCST004571_23 | Iron status biomarkers (total iron binding capacity) | 2.000000e-08 |
| GCST004572_4 | Iron status biomarkers (transferrin saturation) | 2.000000e-08 |
| GCST010002_50 | Refractive error | 4.000000e-34 |
| GCST010142_16 | Fish- and plant-related diet | 2.000000e-10 |
| GCST010142_19 | Fish- and plant-related diet | 4.000000e-10 |
| GCST010142_34 | Fish- and plant-related diet | 7.000000e-09 |
| GCST010142_35 | Fish- and plant-related diet | 8.000000e-09 |
| GCST010142_42 | Fish- and plant-related diet | 1.000000e-08 |
| GCST010142_7 | Fish- and plant-related diet | 3.000000e-12 |
| GCST010142_74 | Fish- and plant-related diet | 9.000000e-09 |
| GCST010142_82 | Fish- and plant-related diet | 3.000000e-08 |
| GCST010702_75 | Subcortical volume (MOSTest) | 3.000000e-11 |
| GCST010703_272 | Brain morphology (MOSTest) | 7.000000e-16 |
| GCST90016674_5 | Liver iron content | 2.000000e-135 |
EFO canonical traits (4, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004461 | iron biomarker measurement |
| EFO:0006334 | total iron binding capacity |
| EFO:0008111 | diet measurement |
| EFO:0004346 | neuroimaging measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
47 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | increases expression, affects binding, increases reaction, decreases expression | 6 |
| (+)-JQ1 compound | increases expression | 5 |
| Air Pollutants | decreases expression, affects cotreatment, increases abundance, increases expression | 4 |
| Benzo(a)pyrene | increases expression, decreases methylation | 3 |
| bisphenol A | decreases expression, increases expression | 2 |
| Acetaminophen | increases expression | 2 |
| Doxorubicin | affects expression | 2 |
| Silicon Dioxide | increases expression | 2 |
| Tobacco Smoke Pollution | decreases expression, affects expression | 2 |
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | decreases expression, increases expression | 2 |
| Particulate Matter | decreases expression, increases abundance | 2 |
| aristolochic acid I | increases expression | 1 |
| UF010 compound | increases acetylation | 1 |
| OTX015 | affects expression | 1 |
| alpha-pinene | affects cotreatment, increases expression, increases abundance | 1 |
| trichostatin A | affects expression | 1 |
| thallium sulfate | decreases expression | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| perfluorooctanoic acid | decreases expression | 1 |
| ferrous chloride | increases expression | 1 |
| methacrylaldehyde | increases abundance, affects cotreatment, increases expression | 1 |
| homosalate | affects cotreatment, increases expression | 1 |
| obeticholic acid | decreases expression | 1 |
| abrine | increases expression | 1 |
| Poly(amidoamine) | increases expression | 1 |
| licochalcone B | increases expression | 1 |
| jinfukang | affects cotreatment, increases expression | 1 |
| incobotulinumtoxinA | decreases expression | 1 |
| Leflunomide | increases expression | 1 |
| Acrolein | affects cotreatment, increases expression, increases abundance | 1 |
Cellosaurus cell lines
30 cell lines: 17 cancer cell line, 10 embryonic stem cell, 3 induced pluripotent stem cell
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_1D62 | HeLa Kyoto EGFP-LaminA/H2B-mCherry | Cancer cell line | Female |
| CVCL_1D63 | HeLa Kyoto EGFP-H2B | Cancer cell line | Female |
| CVCL_1D65 | HeLa Kyoto Mad2-LAP/H2B-mCherry | Cancer cell line | Female |
| CVCL_A2AY | YUMMER1.7 H2B-GFP5 | Cancer cell line | Male |
| CVCL_A5NJ | H7-H2B-RFP | Embryonic stem cell | Female |
| CVCL_A5NK | H14-H2B-RFP | Embryonic stem cell | Male |
| CVCL_A5NL | HUES 17-H2B-RFP | Embryonic stem cell | Male |
| CVCL_A7QQ | U2OS EGFP-H2B | Cancer cell line | Female |
| CVCL_C4SE | CCMB-Me-14-STGG-A1 | Embryonic stem cell | Male |
| CVCL_E7GG | H9 NR4A2-eGFP | Embryonic stem cell | Female |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.